Skip to main content
Erschienen in: Journal of Bone and Mineral Metabolism 4/2019

15.10.2018 | Original Article

Insulin-like growth factor-I is required to maintain muscle volume in adult mice

verfasst von: Satoshi Nakamura, Yuiko Sato, Tami Kobayashi, Takatsugu Oike, Yosuke Kaneko, Kana Miyamoto, Atsushi Funayama, Akihito Oya, Toru Nishiwaki, Morio Matsumoto, Masaya Nakamura, Arihiko Kanaji, Takeshi Miyamoto

Erschienen in: Journal of Bone and Mineral Metabolism | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Insulin-like growth factor-I (IGF-I) is a peptide with diverse functions, among them regulation of embryonic development and bone homeostasis. Serum IGF-I levels decline in the elderly; however, IGF-I function in adults has not been clearly defined. Here, we show that IGF-I is required to maintain muscle mass in adults. We crossed Igf-I flox’d and Mx1 Cre mice to yield Mx1 Cre/Igf-Iflox/flox (IGF-I cKO) mice, and deleted Igf-I in adult mice by polyIpolyC injection. We demonstrate that, although serum IGF-I levels significantly decreased after polyIpolyC injection relative to (Igf-Iflox/flox) controls, serum glucose levels were unchanged. However, muscle mass decreased significantly after IGF-I down-regulation, while bone mass remained the same. In IGF-I cKO muscle, expression of anabolic factors such as Eif4e and p70S6K significantly decreased, while expression of catabolic factors MuRF1 and Atrogin-1 was normal and down-regulated, respectively, suggesting that observed muscle mass reduction was due to perturbed muscle metabolism. Our data demonstrate a specific role for IGF-I in maintaining muscle homeostasis in adults.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
3.
Zurück zum Zitat Liu J-P, Baker J, Perkins AS, Roberteon EJ, Efetratiadie A (1993) Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 75:59–72PubMed Liu J-P, Baker J, Perkins AS, Roberteon EJ, Efetratiadie A (1993) Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 75:59–72PubMed
4.
Zurück zum Zitat DeChiara TM, Efstratiadis A, Robertson EJ (1990) A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting. Nature 345:76–80CrossRef DeChiara TM, Efstratiadis A, Robertson EJ (1990) A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting. Nature 345:76–80CrossRef
5.
Zurück zum Zitat Duvillié B, Cordonnier N, Deltour L, Fo Dandoy-Dron, Itier J-M, Monthioux E, Jami J, Joshi RL, Bucchini D (1997) Phenotypic alterations in insulin-deficient mutant mice. Proc Natl Acad Sci U S A 94:5137–5140CrossRefPubMedPubMedCentral Duvillié B, Cordonnier N, Deltour L, Fo Dandoy-Dron, Itier J-M, Monthioux E, Jami J, Joshi RL, Bucchini D (1997) Phenotypic alterations in insulin-deficient mutant mice. Proc Natl Acad Sci U S A 94:5137–5140CrossRefPubMedPubMedCentral
10.
14.
Zurück zum Zitat Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, Poueymirou WT, Panaro FJ, Na E, Dharmarajan K, Pan ZQ, Valenzuela DM, DeChiara TM, Stitt TN, Yancopoulos GD, Glass DJ (2001) Identification of ubiquitin ligases required for skeletal muscle atrophy (in eng). Science (New York, NY) 294:1704–1708. https://doi.org/10.1126/science.1065874 CrossRef Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, Poueymirou WT, Panaro FJ, Na E, Dharmarajan K, Pan ZQ, Valenzuela DM, DeChiara TM, Stitt TN, Yancopoulos GD, Glass DJ (2001) Identification of ubiquitin ligases required for skeletal muscle atrophy (in eng). Science (New York, NY) 294:1704–1708. https://​doi.​org/​10.​1126/​science.​1065874 CrossRef
17.
Zurück zum Zitat Coleman ME, DeMayo F, Yin KC, Lee HM, Geske R, Montgomery C, Schwartz RJ (1995) Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice (in eng). J Biol Chem 270:12109–12116CrossRefPubMed Coleman ME, DeMayo F, Yin KC, Lee HM, Geske R, Montgomery C, Schwartz RJ (1995) Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice (in eng). J Biol Chem 270:12109–12116CrossRefPubMed
22.
Zurück zum Zitat Li M, Li C, Parkhouse WS (2002) Differential effects of des IGF-1 on Erks, AKT-1 and P70 S6K activation in mouse skeletal and cardiac muscle (in eng). Mol Cell Biochem 236:115–122CrossRefPubMed Li M, Li C, Parkhouse WS (2002) Differential effects of des IGF-1 on Erks, AKT-1 and P70 S6K activation in mouse skeletal and cardiac muscle (in eng). Mol Cell Biochem 236:115–122CrossRefPubMed
25.
Zurück zum Zitat Kell RT, Bell G, Quinney A (2001) Musculoskeletal fitness, health outcomes and quality of life (in eng). Sports Med (Auckland, NZ) 31:863–873CrossRef Kell RT, Bell G, Quinney A (2001) Musculoskeletal fitness, health outcomes and quality of life (in eng). Sports Med (Auckland, NZ) 31:863–873CrossRef
27.
Zurück zum Zitat Juul A, Bang P, Hertel NT, Main K, Dalgaard P, Jorgensen K, Muller J, Hall K, Skakkebaek NE (1994) Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index (in eng). J Clin Endocrinol Metab 78:744–752. https://doi.org/10.1210/jcem.78.3.8126152 CrossRefPubMed Juul A, Bang P, Hertel NT, Main K, Dalgaard P, Jorgensen K, Muller J, Hall K, Skakkebaek NE (1994) Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index (in eng). J Clin Endocrinol Metab 78:744–752. https://​doi.​org/​10.​1210/​jcem.​78.​3.​8126152 CrossRefPubMed
30.
Zurück zum Zitat Hofmann M, Halper B, Oesen S, Franzke B, Stuparits P, Tschan H, Bachl N, Strasser EM, Quittan M, Ploder M, Wagner KH, Wessner B (2015) Serum concentrations of insulin-like growth factor-1, members of the TGF-beta superfamily and follistatin do not reflect different stages of dynapenia and sarcopenia in elderly women. Exp Gerontol 64:35–45. https://doi.org/10.1016/j.exger.2015.02.008 CrossRefPubMed Hofmann M, Halper B, Oesen S, Franzke B, Stuparits P, Tschan H, Bachl N, Strasser EM, Quittan M, Ploder M, Wagner KH, Wessner B (2015) Serum concentrations of insulin-like growth factor-1, members of the TGF-beta superfamily and follistatin do not reflect different stages of dynapenia and sarcopenia in elderly women. Exp Gerontol 64:35–45. https://​doi.​org/​10.​1016/​j.​exger.​2015.​02.​008 CrossRefPubMed
31.
34.
Zurück zum Zitat Grobet L, Pirottin D, Farnir F, Poncelet D, Royo LJ, Brouwers B, Christians E, Desmecht D, Coignoul F, Kahn R, Georges M (2003) Modulating skeletal muscle mass by postnatal, muscle-specific inactivation of the myostatin gene (in eng). Genesis (New York, NY: 2000) 35:227–238. https://doi.org/10.1002/gene.10188 CrossRef Grobet L, Pirottin D, Farnir F, Poncelet D, Royo LJ, Brouwers B, Christians E, Desmecht D, Coignoul F, Kahn R, Georges M (2003) Modulating skeletal muscle mass by postnatal, muscle-specific inactivation of the myostatin gene (in eng). Genesis (New York, NY: 2000) 35:227–238. https://​doi.​org/​10.​1002/​gene.​10188 CrossRef
35.
36.
Zurück zum Zitat Whittemore LA, Song K, Li X, Aghajanian J, Davies M et al (2003) Inhibition of myostatin in adult mice increases skeletal muscle mass and strength (in eng). Biochem Biophys Res Commun 300:965–971CrossRefPubMed Whittemore LA, Song K, Li X, Aghajanian J, Davies M et al (2003) Inhibition of myostatin in adult mice increases skeletal muscle mass and strength (in eng). Biochem Biophys Res Commun 300:965–971CrossRefPubMed
38.
Zurück zum Zitat Bhattacharya I, Pawlak S, Marraffino S, Christensen J, Sherlock SP, Alvey C, Morris C, Arkin S, Binks M (2017) Safety, tolerability, pharmacokinetics, and pharmacodynamics of domagrozumab (PF-06252616), an antimyostatin monoclonal antibody, in healthy subjects. Clin Pharmacol Drug Dev. https://doi.org/10.1002/cpdd.386 CrossRefPubMed Bhattacharya I, Pawlak S, Marraffino S, Christensen J, Sherlock SP, Alvey C, Morris C, Arkin S, Binks M (2017) Safety, tolerability, pharmacokinetics, and pharmacodynamics of domagrozumab (PF-06252616), an antimyostatin monoclonal antibody, in healthy subjects. Clin Pharmacol Drug Dev. https://​doi.​org/​10.​1002/​cpdd.​386 CrossRefPubMed
39.
40.
42.
Zurück zum Zitat Nakao R, Hirasaka K, Goto J, Ishidoh K, Yamada C, Ohno A, Okumura Y, Nonaka I, Yasutomo K, Baldwin KM, Kominami E, Higashibata A, Nagano K, Tanaka K, Yasui N, Mills EM, Takeda S, Nikawa T (2009) Ubiquitin ligase Cbl-b is a negative regulator for insulin-like growth factor 1 signaling during muscle atrophy caused by unloading (in eng). Mol Cell Biol 29:4798–4811. https://doi.org/10.1128/mcb.01347-08 CrossRefPubMedPubMedCentral Nakao R, Hirasaka K, Goto J, Ishidoh K, Yamada C, Ohno A, Okumura Y, Nonaka I, Yasutomo K, Baldwin KM, Kominami E, Higashibata A, Nagano K, Tanaka K, Yasui N, Mills EM, Takeda S, Nikawa T (2009) Ubiquitin ligase Cbl-b is a negative regulator for insulin-like growth factor 1 signaling during muscle atrophy caused by unloading (in eng). Mol Cell Biol 29:4798–4811. https://​doi.​org/​10.​1128/​mcb.​01347-08 CrossRefPubMedPubMedCentral
43.
47.
51.
Zurück zum Zitat Hao W, Tashiro S, Hasegawa T, Sato Y, Kobayashi T, Tando T, Katsuyama E, Fujie A, Watanabe R, Morita M, Miyamoto K, Morioka H, Nakamura M, Matsumoto M, Amizuka N, Toyama Y, Miyamoto T (2015) Hyperglycemia promotes Schwann cell de-differentiation and de-myelination via sorbitol accumulation and Igf1 protein down-regulation (in eng). J Biol Chem 290:17106–17115. https://doi.org/10.1074/jbc.M114.631291 CrossRefPubMedPubMedCentral Hao W, Tashiro S, Hasegawa T, Sato Y, Kobayashi T, Tando T, Katsuyama E, Fujie A, Watanabe R, Morita M, Miyamoto K, Morioka H, Nakamura M, Matsumoto M, Amizuka N, Toyama Y, Miyamoto T (2015) Hyperglycemia promotes Schwann cell de-differentiation and de-myelination via sorbitol accumulation and Igf1 protein down-regulation (in eng). J Biol Chem 290:17106–17115. https://​doi.​org/​10.​1074/​jbc.​M114.​631291 CrossRefPubMedPubMedCentral
Metadaten
Titel
Insulin-like growth factor-I is required to maintain muscle volume in adult mice
verfasst von
Satoshi Nakamura
Yuiko Sato
Tami Kobayashi
Takatsugu Oike
Yosuke Kaneko
Kana Miyamoto
Atsushi Funayama
Akihito Oya
Toru Nishiwaki
Morio Matsumoto
Masaya Nakamura
Arihiko Kanaji
Takeshi Miyamoto
Publikationsdatum
15.10.2018
Verlag
Springer Japan
Erschienen in
Journal of Bone and Mineral Metabolism / Ausgabe 4/2019
Print ISSN: 0914-8779
Elektronische ISSN: 1435-5604
DOI
https://doi.org/10.1007/s00774-018-0964-6

Weitere Artikel der Ausgabe 4/2019

Journal of Bone and Mineral Metabolism 4/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.